证券代码：600479 证券简称：千金药业 公告编号：2025-064 株洲千金药业股份有限公司 关于召开2026年第一次临时股东会 的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 2026年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2026年1月12日 9点30分 召开地点：湖南省株洲市天元区株洲大道801号千金药业三楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026年1月12日 至2026年1月12日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的9:15- 15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投 ...

证券日报网讯 12月19日，千金药业发布公告称，公司第十一届董事会第十五次会议审议通过《关于提 名许大为先生为公司第十一届董事会董事候选人的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯12月19日晚间，千金药业（600479）发布公告称，公司将于2026年1月12日召开2026年第 一次临时股东会。 ...

（记者 曾健辉） 每经AI快讯，千金药业（SH 600479，收盘价：10.46元）12月19日晚间发布公告称，公司定于2026年1 月12日在公司会议室召开2026年第一次临时股东会，审议公司第十一届董事会第十五次会议提交的议 案。 2025年1至6月份，千金药业的营业收入构成为：药品生产占比55.83%，药品批发零售占比41.72%，其 他行业占比6.91%，中药材及饮片生产占比1.64%，内部抵销占比-6.1%。 截至发稿，千金药业市值为51亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ ...

第一条 为进一步规范株洲千金药业股份有限公司（以下简称 "公司"）及其控股子公司对外捐赠行为，加强公司对捐赠事项的管 理，全面、有效地提升和宣传公司品牌及企业形象，维护公司股东、 债权人及员工利益，根据《中华人民共和国公司法》《中华人民共和 国公益事业捐赠法》《上海证券交易所股票上市交易规则》及《株洲 千金药业股份有限公司章程》（以下简称"《公司章程》"），制订 本制度。 株洲千金药业股份有限公司 对外捐赠管理制度 第一章 总则 第二条 本制度适用于公司，控股子公司可参照执行。 第三条 本制度所称"对外捐赠"，是指公司以公司名义在帮助社 会抵抗自然灾害、构建和谐生态环境、救助危困群体、增加社会福利 等公益性社会活动中捐赠公司财产的行为。 第四条 实施对外捐赠坚持自愿、量力而行的原则，捐赠批准程 序以及行为的实施必须符合本制度和有关法律、法规、规章以及《公 司章程》的规定。 第二章 对外捐赠的形式及范围 第五条 公司可以用于对外捐赠的财产包括现金和实物资产（包 括库存商品、固定资产及其他有形资产等）。公司生产经营需用的主 要固定资产、持有的股权和债权、国家特准储备物资、国家财政拨款、 受托代管财产、已设置担保物 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-064 株洲千金药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 12 日 9 点 30 分 召开地点：湖南省株洲市天元区株洲大道 801 号千金药业三楼会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七) 涉及公开征集股东投票权 (五) 网络投票的系统、 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二〇二五年十二月十九日，株洲千金药业股份有限公司（以下简 称"公司"）第十一届董事会第十五次会议以通讯表决方式召开。本 次会议应表决董事 8 人，实际表决董事 8 人。会议情况符合《公司法》 《公司章程》的有关规定。会议审议并通过以下议案： 株洲千金药业股份有限公司 第十一届董事会第十五次会议决议公告 一、关于提名许大为先生为公司第十一届董事会董事候选人的议案 根据公司控股股东提名，经公司董事会提名委员会审议通过，董 事会同意提名许大为先生为公司第十一届董事会董事候选人。 证券代码：600479 证券简称：千金药业 公告编号：2025-063 四、关于召开株洲千金药业股份有限公司 2026 年第一次临时股东会 的议案 公司定于 2026 年 1 月 12 日在公司会议室召开 2026 年第一次临 时股东会，审议公司第十一届董事会第十五次会议提交的议案。 表决结果：8 票赞成，0 票反对，0 票弃权。 该议案尚需提交公司股东会审议。 二、关于制定《株洲千金药业股份有限公司对外捐赠管 ...

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received approval for the registration certificate of hydrochloride rufinamide tablets from the National Medical Products Administration [1] - Qianjin Pharmaceutical's revenue composition for the first half of 2025 is as follows: 55.83% from drug production, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5 billion yuan [1]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

关于变更持续督导独立财务顾问主办人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 国投证券股份有限公司（以下简称"国投证券"）为株洲千金药业股份有限 公司（以下简称"公司"）发行股份及支付现金购买资产暨关联交易（以下简称 "本次重组"）的独立财务顾问，国投证券原指定颜永彬先生、杨晓波先生作为 独立财务顾问主办人。 本次变更后，公司本次重组的持续督导独立财务顾问主办人为颜永彬先生和 黄艺庭先生，持续督导期至中国证券监督管理委员会和上海证券交易所规定的持 续督导义务结束为止。 特此公告。 证券代码：600479 证券简称：千金药业 公告编号：2025-062 株洲千金药业股份有限公司 公司于近日收到国投证券出具的《关于变更株洲千金药业股份有限公司 2024 年度发行股份及支付现金购买资产暨关联交易项目独立财务顾问主办人的 通知》，其原指派的独立财务顾问主办人杨晓波先生因个人工作变动原因不再担 任公司本次重组持续督导独立财务顾问主办人，并指定黄艺庭先生（简历附后） 接替本次重组后续持续督导等相关工作，继续履行相关职责。 20 ...